This volume will describe both growth-inhibitory and mucin-depleting effects of bromelain and N-acetylcysteine, on their own or in combination, in cancer. It will coherently review the pathophysiological aspects of the mucin glycoproteins in malignancies and provide an updated account of the status of bromelain and N-acetylcysteine in cancer therapy. The volume will develop the idea of using these two drugs as a combination formulation for mucin-depleting effects.

This book, written by experts from across the world, provides a comprehensive, up-to-date overview covering all aspects of posterior fossa neoplasms in pediatric patients, including medulloblastoma, ependymoma, cerebellar astrocytoma, atypical teratoid/rhabdoid tumor, chordoma, brain stem tumors, and rarer entities. For each tumor type, individual chapters are devoted to genetics, radiological evaluation using advanced imaging techniques, surgery, pathology, oncology, and radiation treatment. In addition, a separate section describes the various surgical approaches that may be adopted and offers guidance on the treatment of hydrocephalus and the role of intraoperative mapping and monitoring. Useful information is also provided on anatomy, clinical presentation, neurological evaluation, and molecular biology. The book closes by discussing in detail immediate postoperative care, the management of surgical complications, and longer-term rehabilitation and support. Posterior fossa tumors are the most common pediatric brain tumors but are often difficult to treat owing to their proximity to critical brain structures and their tendency to cause marked intracranial hypertension. Practitioners of all levels of experience will find Posterior Fossa Tumors in Children to be a richly illustrated, state of the art guide to the management of these tumors that will serve as an ideal reference in clinical practice.

This issue of Rheumatic Disease Clinics of North America provides foundational and in-depth information about paraneoplastic and cancer treatment-related rheumatic disorders, in which every practicing rheumatologist should be well-versed.? Topics covered include neoplasm risk in patients with rheumatic diseases; neoplasm risk of anti-rheumatic therapy; rheumatologic laboratory findings in malignancy; rheumatic manifestations of primary and metastatic bone tumors and paraneoplastic bone disease; neoplastic/paraneoplastic synovitis; neoplastic/paraneoplastic dermatitis, fasciitis, and panniculitis; neoplastic/paraneoplastic vasculitis, vasculopathy, and hypercoagulability; neoplastic/paraneoplastic myalgias and myositis; and less-common neoplastic/paraneoplastic syndromes.

In this issue of Surgical Oncology Clinics of North America, Guest Editor Mark Krasna and colleagues discuss a wide range of topics devoted to lung cancer.? Articles focus on pathology; updated staging systems; epidemiology of lung cancer - smoking, second hand smoke, and genetics; molecular markers for incidence, prognosis, and response to therapy; screening; diagnostic work-up; non-invasive staging techniques; surgical resection; the role of surgery following induction therapy for stage III NSCLC; the role of adjuvant chemotherapy in NSCLC (stages I-III); and much more.

Carcinoma of the lung is one of the most prevalent and aggressive types of cancer, and rates of lung cancer are on the rise.? This issue gives a comprehesive review of the most recent advances in Lung Cancer.? Epidemiology, etiology, and prevention of lung cancer is first discussed, followed by articles on pre-invasive evaluation and management, screening, pathology and molecular biology.? There is an article on the approach to the ground glass nodule.? Of great importance is the revised staging classification of Lung Cancer, which is discussed here in detail.? Articles on PET imaging, interventional pulmonary, and functional evaluation before Lung Resection are also included.? The issue then focuses on advances in treatment for early stage lung cancer, hgih risk patients with early stage lung cancer, advances in the treatment of Advanced Stage Lung Cancer, Small Cell Lung Cancer, and gene therapy for lung neoplasms.

Topics for this issue will include: Epidemiology of RCC;New Insights into the Biology of RCC;Pathology of Renal Neoplasms;Imaging in RCC;Small Renal Tumors: Prognosis and Management;The Role of Surgery in the management of RCC: Nephrectomy and metastatectomy;Cytoreductive Nephrectomy: Rationale and current Applications;Adjuvant Therapies in RCC and Management of Side Effects from Current Therapies in RCC

This book aims to provide an up-to-date review of the literature in each of the major areas relating to the management of older urological cancer patients, and makes recommendations for best practice and future research. The authors come from a broad geographic spread including the UK, mainland Europe and North America to ensure a worldwide relevance.

The difference among pluripotent stem cells, multipotent stem cells, and unipotent stem cells is pointed out. Vast therapeutic applications of the following specific stem cells in disease and tissue injury are discussed: human embryonic stem cells, human mesenchymal stem cells, germ cell-derived pluripotent stem cells, induced pluripotent stem cells, human umbilical cord blood-derived stem cells, breast tumor stem cells,and hematopoietic stem cells. Because of the potential of human embryonic stem cells to produce unlimited quantities of any human cell type, considerable focus is placed on their therapeutic potential. Because of their pluripotency, these cells have been used in various applications such as tissue engineering, regenerative medicine, pharmacological and toxicological studies, and fundamental studies of cell differentiation. The formation of embryoid bodies, which are three-dimensional aggregates of embryonic stem cells, is explained as this is the first step in cell differentiation. Such embryoid body culture has been widely used as a trigger for the in vitro differentiation of embryonic stem cells. The basic capacity of self-renewal of human embryogenic stem cells is explained. The role of TGF-beta in the propagation of human embryonic stem cells is discussed. The differentiation of human embryonic stem cells into neurons, hepatocytes, cardiomyocytes, and retinal cells is fully explained. Donor policies for hematopoietic stem cells are also explained.

Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.

This book aims to provide an up-to-date review of the literature in each of the major areas relating to the management of older colorectal cancers patients, and makes recommendations for best practice and future research. The authors come from a broad geographic spread including the UK, mainland Europe and North America to ensure a worldwide relevance.

The Third Edition of this classic compendium, Vitamin D, is the most comprehensive, authoritative reference available in the field. In two volumes and over 100 chapters, the editors and authors have marshaled all currently available data on the basic mechanisms, normal physiology and effects on disease of Vitamin D; they have laid out for the reader up-to-date and expert information on the role of vitamin D in health and many disorders. With new chapters on multiple cancers, this complete reference work is essential for anyone working in endocrinology, osteology, bone biology, or cancer research. Volume One chapters cover the chemistry and metabolism of vitamin D, role in mineralization, other target organs, and general physiological effects. Volume Two is more clinically oriented addressing deficiency problems (including diagnosis, interactions in the endocrine system, and involvement in malignancies). Volumes One and Two are now sold separately in print. Volume One ISBN: 9780123870353; Volume Two ISBN: 9780123870346.

Vegetables, Whole Grains and their Derivatives in Cancer Prevention looks in detail at the evidence regarding the effects and mechanisms of action of potentially cancer-preventive components and their sources from plant kingdom. The book covers current knowledge on certain foods and their constituents in cancer prevention, such as cruciferous and green leafy vegetables, nuts and seeds, whole grains, tomato lycopene and carotenoids, alliums and their sulphur and selenium constituents, and capsaicinoids from chilli peppers. It focuses not only on single compounds but aims to widen the view by discussing a whole-diet approach in cancer prevention. A single component may lose its chemopreventive efficacy when isolated from the food matrix and in many cases isolated and concentrated components as supplements may actually induce tumor development. Apart from describing the effects and mechanisms of action, the chapters also contain information on intake, bioavailability, metabolism and possible toxic effects of foods and components presented. Evaluation and comparison of the data from mechanistic studies in vitro with those from animal experiments in vivo form a basis for applying the current knowledge to human nutrition in the field of carcinogenesis. With contributions from leading experts in the field, this book is an invaluable resource for scientists and professionals working in cancer research, as well as individuals involved in food and nutrition.

Cancer is a multifaceted disease and overwhelmingly increasing experimental evidence has helped us to develop a deeper understanding of the role of signal transduction cascades in cancer development and progression. Tissue microarrays and next generation sequencing technologies have assisted us to gather missing pieces of jigsaw puzzle and we now know that deregulation of spatio-temporally controlled signaling cascades play fundamental role in metastasis and resistance against wide ranging therapeutics. This book offers a balanced overview of the rapidly emerging cutting edge research in molecular oncology and good source of knowledge for established oncologists, basic and medical students and pharmaceutical industry associated R&D departments.

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Frederick Greene, focuses on Surgical Oncology in the Community Cancer Center. An array of experts have come together to explore topics on Sarcoma Management, Minimally Invasive Esophagectomy, Multidisciplinary Clinics and the Surgeon's Role in the Hospital Cancer Program, Breast Cancer Care in the Community Cancer Center, Lumpectomy versus Mastectomy Rates in the Community Setting, American College of Surgeons Oncology Group trials and the Community Surgeon, Quality Surgical Oncology Care in the Community: Training versus Hospital Volume, The Impact of Dedicated Tumor Boards in Clinical Trials, The National Accreditation Program for Breast Centers: Quality Improvement Through Standard Setting, and much more.

Dr. Gilligan has recruited global experts to contribute articles on the topic of testes cancer.? The issue is organized to mimic the clinical process of detection, treatment, and management. Included in the issue are articles on the biology, interpretation, and imaging of germ cell tumors; early stage and stage II of seminomas and nonseminomas; first, second, and third line of chemotherapy for disseminated germ cell tumors, resection of residual masses, and treatment of brain metastases.

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.? Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.? This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.

This book analyzes all aspects of modern multimodal treatment of locally recurrent rectal cancer in the pelvis in order to offer a panoramic overview of the different therapeutic options and enable the reader to balance their benefits and drawbacks. Indications for surgery and the surgical techniques themselves, including reconstruction techniques after major exenterative surgery, are clearly described and evaluated. The role of new imaging tools, such as MRI and PET-CT, in staging recurrences and guiding therapy is assessed and detailed consideration is given to the use of neoadjuvant and iterative radiotherapy and the indications for systemic chemotherapy. Morbidity, mortality, oncologic outcomes, and quality of life issues are carefully analyzed and options for pain control and palliation are examined. Finally, a national survey is presented on the state of the art in the surgical treatment of locally recurrent rectal cancer in Italy. While there has been a dramatic fall in the incidence of local pelvic recurrences, their treatment remains a major clinical challenge which requires a multidisciplinary approach and careful selection of the most appropriate strategy in each case. This book will aid practitioners in making the correct decisions in individual patients.

This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.

Metastatic disease is the most lethal aspect of human malignancies, making the understanding and continued research of the process of metastasis a crucial step in treating cancer. The proposed book, entitled "Experimental and Clinical Metastasis: A Comprehensive Review" aims to provide a clear and extensive review of the clinical and experimental implications of metastatic disease. This work focuses on recent contributions to the field of metastasis, and will highlight crucial findings in the molecular understanding of disseminated disease as well as standard and personalized medicine currently being investigated in the clinic. Topics will include, among many, gene properties of metastatic cells, molecular mechanisms of tumour growth and spread, animal models of metastasis, and clinical implications, markers and treatment for metastatic disease. With the participation of worldwide experts in the field of oncology, from major academic and government centres, this book will provide a leading manual for the study of the metastatic process, from benchside science to bedside care. In this light, the proposed book will facilitate classroom learning for both medical and graduate students, as well as serve as a tool for physicians and researchers interested in the metastatic process. In addition, this book will include the latest advances in basic science as well as leading technologies and theories of targeting metastatic cells. Most importantly, not only will basic and clinical aspects be discussed, but furthermore, the translational aspect of research in metastatic diseases will be emphasized.

Guest Editors Jeffrey Bruce and Andrew Parsa explore Pinneal Region Tumors in this issue of Neurosurgery Clinics.? Topics concentrate on areas such as pathology, radiographic features, open surgical approaches, endoscopic surgical approaches, clinical outcomes after treatment of pineocytoma, clinical outcomes after treatment of pineoblastoma, clinical outcomes after treatment of germ cell tumors, pineal cysts: radiographic criteria and clinical management, ? opthamologic signs and symptoms associated with pineal region tumors, history of pineal region tumor surgery and management, and radiation treatment algorithms

Pancreatic ductal adenocarcinoma is the fifth leading cause of cancer death in the USA. Pancreatic cancer develops as a result of the accumulation of genetic and epigenetic alterations in cancer-causing genes such as oncogenes and tumor-suppressor genes. The second edition of Pancreatic Cancer: Methods and Protocols provides a broad range of protocols for molecular, cellular, pathological, and statistical analyses of sporadic and familial pancreatic cancer. It covers topics from in-vitro cell cultures to in-vivo mouse models, DNA to protein manipulation, and genetic and epigenetic analyses to treatment development. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, written by highly renowned investigators with expertise in pancreatic cancer, Pancreatic Cancer: Methods and Protocols, Second Edition is an invaluable source of proven protocols to those who are interested in joining the fight against pancreatic cancer.

Oncothermia is the next generation medical innovation that delivers selective, controlled and deep energy for cancer treatment. The basic principles for oncothermia stem from oncological hyperthermia, the oldest approach to treating cancer. Nevertheless, hyperthermia has been wrought with significant controversy, mostly stemming from shortcomings of controlled energy delivery. Oncothermia has been able to overcome these insufficiencies and prove to be a controlled, safe and efficacious treatment option. This book is the first attempt to elucidate the theory and practice of oncothermia, based on rigorous mathematical and biophysical analysis, not centered on the temperature increase. It is supported by numerous in-vitro and in-vivo findings and twenty years of clinical experience. This book will help scientists, researchers and medical practitioners in understanding the scientific and conceptual underpinnings of oncothermia and will add another valuable tool in the fight against cancer. Professor Andras Szasz is the inventor of oncothermia and the Head of St Istvan University's Biotechnics Department in Hungary. He has published over 300 papers and lectured at various universities around the world. Dr. Oliver Szasz is the managing director of Oncotherm, the global manufacturer and distributor of medical devices for cancer treatment used in Europe & Asia since the late 1980s. Dr. Nora Szasz is currently a management consultant in healthcare for McKinsey & Co.